|
Video: What is a Stock Split?
|
|
4D Molecular Therapeutics is a clinical-stage gene therapy company engaging the development of product candidates using its targeted and evolved adeno-associated viruses vectors. Co. has built a portfolio of gene therapy product candidates, with five product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa, 4D-150 for the treatment of wet age-related macular degeneration, 4D-110 for the treatment of choroideremia, 4D-310 for the treatment of Fabry disease, and 4D-710 for the treatment of cystic fibrosis lung disease. According to our 4D Molecular Therapeutics stock split history records, 4D Molecular Therapeutics has had 0 splits. | |
|
4D Molecular Therapeutics (FDMT) has 0 splits in our 4D Molecular Therapeutics stock split history database.
Looking at the 4D Molecular Therapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into 4D Molecular Therapeutics shares, starting with a $10,000 purchase of FDMT, presented on a split-history-adjusted basis factoring in the complete 4D Molecular Therapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
12/14/2020 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$40.50 |
|
End price/share: |
$31.86 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-21.33% |
|
Average Annual Total Return: |
-7.04% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$7,867.83 |
|
Years: |
3.28 |
|
|
|
|
|